Deans' stroke musings: FDA approves first blood sugar monitor without finger pricks

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, April 29, 2018

FDA approves first blood sugar monitor without finger pricks

With any brains at all in the stroke medical world we could get an INR monitor like this. But since there seems to not even be two functioning neurons in the stroke medical world nothing will happen.
https://www.statnews.com/2017/09/28/fda-approves-blood-sugar-monitor-without-finger-pricks/

U.S. regulators have approved the first continuous blood sugar monitor for diabetics that doesn’t need backup finger prick tests.

Current models require users to test a drop of blood twice daily to calibrate, or adjust, the monitor.

The pain of finger sticks and the cost of testing supplies discourage many people from keeping close tabs on their blood sugar, which is needed to manage insulin use and adjust what they eat.

SPONSOR CONTENT

Non-opioid EXPAREL may provide long-lasting pain control for total knee replacement surgery

A Total Knee Replacement (TKR) is one of the most commonly performed orthopedic procedures. Read about how non-opioid EXPAREL may provide long-lasting pain control.

Pacira Pharmaceuticals, Inc. and DePuy Synthes Companies

Abbott’s new FreeStyle Libre Flash Glucose Monitoring System, approved Wednesday by the Food and Drug Administration, uses a small sensor attached to the upper arm. Patients wave a reader device over it to see the current blood sugar level and changes over the past eight hours.

Most of the 30 million Americans with diabetes use standard glucose meters, which require multiple finger pricks each day and only show current sugar level. More-accurate continuous glucose monitoring devices are used by about 345,000 Americans.

But most don’t do the finger pricks to calibrate them and may get inaccurate readings, said Dr. Timothy Bailey, who helped test FreeStyle Libre.
“We’re able to lower blood sugar safely” with this technology, said Bailey, director of the Advanced Metabolic Care and Research Institute in California. He receives consulting fees from various diabetes device makers.
Too-high blood sugar levels can damage organs and lead to heart attacks, strokes, blindness and amputations. Very low blood sugar can cause seizures, confusion and loss of consciousness.
Abbott’s device was approved for adults with type 1 or type 2 diabetes and should be available in pharmacies within months. The company, based near Chicago, did not disclose the price of the reader or the sensors.
Abbott’s system can’t be used with an insulin pump, a device worn against the skin that allows users to inject insulin as needed, but the company is planning improvements to eventually enable that.
Rival Medtronic this spring launched a device in which the insulin pump automatically responds to blood sugar changes recorded by the sensor and either withholds or injects insulin as needed.